Long-term survival of patients with acute myeloid leukemia: Updated results from two trials evaluating postinduction chemotherapy

Cancer

Volumn 80, Issue 11 SUPPL., 1997, Pages 2186-2190

  Bloomfield, Clara D ^a,e   Herzig, Geoffrey P ^a,d   Peterson, Bruce A ^b   Wolff, Steven N ^c  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c VANDERBILT UNIVERSITY   (United States)

^d North American Transplant Group   (United States)

^e OHIO STATE UNIVERSITY   (United States)

Author keywords

Acute myeloid leukemia; Cure; Postinduction chemotherapy; Prolonged follow up

Indexed keywords

CYTARABINE; TIOGUANINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

EID: 0030710229     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-0142(19971201)80:11+<2186::aid-cncr4>3.0.co;2-g     Document Type: Review

References (2)

1. Peterson BA, Bloomfield CD. Long-term disease-free survival in acute nonlymphocytic leukemia. Blood 1981; 57:1144-7.
2. Wolff SN, Herzig RH, Fay JW, Phillips GL, Lazarus HM, Flexner JM, et al. High-dose cytarabine and daunorubicin as consolidation therapy for acute myeloid leukemia in first remission: long-term follow-up results. J Clin Oncol 1989;7:1260-7.